ObjectiveTo investigate the clinical efficacy of TACE combined with sorafenib in the treatment of primary liver cancer and its effect on tumor angiogenesis and liver function. Methods68 patients with advanced primary liver cancer admitted to our hospital and Guangzhou Nanfang Hospital liver disease center were selected. They were randomly divided into the study group and the control group, 34 cases in each group. The control group were treated with transcatheter arterial chemoembolization (TACE), and the study group were treated with TACE combined with sorafenib. The clinical efficacy, serum VEGF and liver function, complications and prognosis were compared between the two groups. ResultsAfter 1 months of treatment, the objective remission rate (CR+PR) of the study group was 50%, and that of the control group was 20.6%. The difference between the two groups was statistically significant (P＜0.05). The levels of serum VEGF and ALT and TBil in the two groups were decreased, and the levels of VEGF and ALT in the study group were lower than those in the control group (P＜0.05). There was no significant difference in the incidence of complications between the two groups (P＞0.05). The 1 year survival rate of the study group was 73.5%, while that of the control group was 50%. The difference between the two groups was statistically significant (P＜0.05). ConclusionThe effect of sorafenib combined with TACE in the treatment of patients with advanced liver cancer is significant. It can effectively inhibit the formation of tumor vessels, have less effect on the liver function, and have a better prognosis, which has a certain clinical value.

无